Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zidesamtinib (NVL-520) is an orally active, selective, potent, and blood-brain-barrier-crossing inhibitor of ROS1 fusion and resistance mutations, inhibits ROS1 and ROS1 G2032R, and can be used in the study of non-small-cell lung cancer and solid tumors.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 45,000 | |||
5 mg | 在庫あり | ¥ 113,500 | |||
10 mg | 在庫あり | ¥ 190,500 | |||
25 mg | 在庫あり | ¥ 340,000 | |||
50 mg | 在庫あり | ¥ 450,000 | |||
100 mg | 在庫あり | ¥ 617,500 |
説明 | Zidesamtinib (NVL-520) is an orally active, selective, potent, and blood-brain-barrier-crossing inhibitor of ROS1 fusion and resistance mutations, inhibits ROS1 and ROS1 G2032R, and can be used in the study of non-small-cell lung cancer and solid tumors. |
In vivo | Female athymic Nude-Foxn1nu mice were subcutaneously implanted with tumor fragments from the CTG-0848 model. Zidesamtinib (0.04, 0.2, 1, 5, 15 mg/kg; oral gavage twice daily for 21 days) inhibited tumor volumes[1]. |
別名 | NVL-520 |
分子量 | 419.455 |
分子式 | C22H22FN7O |
CAS No. | 2739829-00-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (71.52 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zidesamtinib 2739829-00-4 Tyrosine Kinase/Adaptors ROS Kinase NVL-520 NVL520 NVL 520 Inhibitor inhibitor inhibit